Catalyst Pharmaceuticals Inc
$
3.61
0.03 (0.84%)
| Volume: | 842,288 | Avg Vol (1m): | 3,026,260 |
| Market Cap $: | 371.29 Mil | Enterprise Value $: | 325.66 Mil |
| P/E (TTM): | 0.00 | P/B: | 7.25 |
| Earnings Power Value | 0.3 |
| Net Current Asset Value | 0.44 |
| Tangible Book | 0.5 |
| Projected FCF | -1.21 |
| Median P/S Value | 8.97 |
| Graham Number | 0 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
1Y (-%)
Manual of Stocks™ Web
Financial Strength : 9/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | No Debt |
Cash-To-Debt ranked
higher than
97.32%
of
859
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
CPRX:
No Debt
Ranked among companies with meaningful Cash-To-Debt only.
| N/A |
| Equity-to-Asset | 0.84 |
Equity-to-Asset ranked
lower than
100.00%
of
788
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
CPRX:
0.84
Ranked among companies with meaningful Equity-to-Asset only.
|
Equity-to-Asset range over the past 10 years
Min: 0.84, Med: 0.84, Max: 0.95
Current: 0.84
|
| Interest Coverage | No Debt |
Interest Coverage ranked
higher than
97.38%
of
648
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 2689668, Med: 86.08, Min: 0.01
CPRX:
No Debt
Ranked among companies with meaningful Interest Coverage only.
| N/A |
| Piotroski F-Score | 4 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 18.17 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | 35.69 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC -2442.07%
WACC 19.71%
| ||
Profitability & Growth : 4/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | -234.40 |
Operating Margin ranked
lower than
100.00%
of
801
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
CPRX:
-234.4
Ranked among companies with meaningful Operating Margin only.
|
Operating Margin range over the past 10 years
Min: -7059, Med: -3940.95, Max: -234.4
Current: -234.4
|
| Net Margin % | -223.58 |
Net Margin ranked
lower than
100.00%
of
802
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
CPRX:
-223.58
Ranked among companies with meaningful Net Margin only.
|
Net Margin range over the past 10 years
Min: -6800.8, Med: -3810.01, Max: -223.58
Current: -223.58
|
| ROE % | -46.19 |
ROE ranked
lower than
80.41%
of
832
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
CPRX:
-46.19
Ranked among companies with meaningful ROE only.
|
ROE range over the past 10 years
Min: -137.75, Med: -53.2, Max: -30.62
Current: -46.19
|
| ROA % | -42.24 |
ROA ranked
lower than
83.24%
of
871
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
CPRX:
-42.24
Ranked among companies with meaningful ROA only.
|
ROA range over the past 10 years
Min: -105.81, Med: -45.7, Max: -28.97
Current: -42.24
|
| ROC (Joel Greenblatt) % | -13093.18 |
ROC (Joel Greenblatt) ranked
lower than
97.31%
of
855
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
CPRX:
-13093.18
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
|
ROC (Joel Greenblatt) range over the past 10 years
Min: -26055.36, Med: -15666.5, Max: -7059.65
Current: -13093.18
|
| 3-Year Total EBITDA Growth Rate | -20.10 |
3-Year EBITDA Growth Rate ranked
lower than
62.93%
of
704
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 299.6, Med: 7.3, Min: -343.2
CPRX:
-10.9
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
|
3-Year EBITDA Growth Rate range over the past 10 years
Min: -51.2, Med: -1.7, Max: 30.7
Current: -10.9
|
| 3-Year EPS w/o NRI Growth Rate | -9.70 |
3-Year EPS w/o NRI Growth Rate ranked
lower than
55.66%
of
663
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 385.8, Med: 8.9, Min: -403.2
CPRX:
-9.7
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
|
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -48.5, Med: -7.1, Max: 33.7
Current: -9.7
|
» CPRX's 30-Y Financials
Financials (Next Earnings Date: 2019-08-08)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:CPRX
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Drug Manufacturers » Drug Manufacturers - Specialty & Generic   NAICS : 325412   SIC : 2834 |
| Compare | SZSE:002864 NYSE:DPLO XKRX:249420 TPE:3705 HKSE:02633 XKRX:243070 XKRX:065660 XCNQ:ACRG.U TSX:FIRE XCNQ:FONE TSXV:XLY NAS:COLL SZSE:000790 BSP:OFSA3 ASX:NXS TSE:4577 XKRX:234080 SHSE:603168 NAS:OPTN SZSE:300519 |
| Traded in other countries | CN2.Germany |
| Address | 355 Alhambra Circle, Suite 1250, Coral Gables, FL, USA, 33134 |
| Catalyst Pharmaceuticals Inc is a biopharmaceutical company. The company is engaged in the development and commercialization of therapies for people with rare debilitating diseases, chronic neuromuscular and neurological diseases. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| Forward PE Ratio | 39.84 |
Forward P/E ranked
lower than
100.00%
of
111
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 322.58, Med: 21.6, Min: 5.03
CPRX:
39.84
Ranked among companies with meaningful Forward P/E only.
| N/A |
| PB Ratio | 7.25 |
PB Ratio ranked
lower than
69.35%
of
819
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
CPRX:
7.25
Ranked among companies with meaningful PB Ratio only.
|
PB Ratio range over the past 10 years
Min: 2.35, Med: 9.33, Max: 29.61
Current: 7.25
|
| PS Ratio | 28.66 |
PS Ratio ranked
lower than
100.00%
of
775
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
CPRX:
28.66
Ranked among companies with meaningful PS Ratio only.
|
PS Ratio range over the past 10 years
Min: 16.8, Med: 71.2, Max: 582
Current: 28.66
|
| EV-to-EBIT | -10.74 |
EV-to-EBIT ranked
lower than
100.00%
of
572
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
CPRX:
-10.74
Ranked among companies with meaningful EV-to-EBIT only.
|
EV-to-EBIT range over the past 10 years
Min: -23.6, Med: -7.9, Max: -1.5
Current: -10.74
|
| EV-to-EBITDA | -10.75 |
EV-to-EBITDA ranked
lower than
100.00%
of
597
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
CPRX:
-10.75
Ranked among companies with meaningful EV-to-EBITDA only.
|
EV-to-EBITDA range over the past 10 years
Min: -23.8, Med: -8, Max: -1.5
Current: -10.75
|
| EV-to-Revenue | 25.15 |
EV-to-Revenue ranked
lower than
100.00%
of
795
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
CPRX:
25.15
Ranked among companies with meaningful EV-to-Revenue only.
|
EV-to-Revenue range over the past 10 years
Min: 14.2, Med: 73.5, Max: 491
Current: 25.15
|
| Current Ratio | 6.08 |
Current Ratio ranked
higher than
96.84%
of
855
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
CPRX:
6.08
Ranked among companies with meaningful Current Ratio only.
|
Current Ratio range over the past 10 years
Min: 0.75, Med: 15.35, Max: 54.56
Current: 6.08
|
| Quick Ratio | 6.07 |
Quick Ratio ranked
higher than
96.84%
of
855
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
CPRX:
6.07
Ranked among companies with meaningful Quick Ratio only.
|
Quick Ratio range over the past 10 years
Min: 0.75, Med: 15.35, Max: 54.56
Current: 6.07
|
| Days Inventory | 6.52 |
Days Inventory ranked
lower than
100.00%
of
755
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
CPRX:
6.52
Ranked among companies with meaningful Days Inventory only.
|
Days Inventory range over the past 10 years
Min: 0, Med: 0, Max: 6.52
Current: 6.52
|
| Days Sales Outstanding | 204.40 |
Days Sales Outstanding ranked
lower than
100.00%
of
770
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
CPRX:
204.4
Ranked among companies with meaningful Days Sales Outstanding only.
|
Days Sales Outstanding range over the past 10 years
Min: 0, Med: 0, Max: 204.4
Current: 204.4
|
| Days Payable | 626.81 |
Days Payable ranked
lower than
100.00%
of
758
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
CPRX:
626.81
Ranked among companies with meaningful Days Payable only.
|
Days Payable range over the past 10 years
Min: 0, Med: 0, Max: 626.81
Current: 626.81
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Share Buyback Rate | -7.40 |
3-Year Share Buyback Rate ranked
lower than
71.10%
of
571
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 100, Med: -5.3, Min: -815
CPRX:
-7.4
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
|
3-Year Share Buyback Rate range over the past 10 years
Min: -74.4, Med: -26, Max: -7.4
Current: -7.4
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Tangible-Book | 7.22 |
Price-to-Tangible-Book ranked
lower than
59.28%
of
749
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 972.22, Med: 3.33, Min: 0.05
CPRX:
7.22
Ranked among companies with meaningful Price-to-Tangible-Book only.
|
Price-to-Tangible-Book range over the past 10 years
Min: 1.25, Med: 3.64, Max: 10.24
Current: 7.22
|
| Price-to-Median-PS-Value | 0.40 |
Price-to-Median-PS-Value ranked
lower than
100.00%
of
743
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
CPRX:
0.4
Ranked among companies with meaningful Price-to-Median-PS-Value only.
|
Price-to-Median-PS-Value range over the past 10 years
Min: 0.39, Med: 0.73, Max: 5.33
Current: 0.4
|
| Earnings Yield (Joel Greenblatt) % | -9.31 |
Earnings Yield (Greenblatt) ranked
lower than
82.70%
of
867
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
CPRX:
-9.31
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
|
Earnings Yield (Greenblatt) range over the past 10 years
Min: -68.8, Med: -12.7, Max: -4.2
Current: -9.31
|
More Statistics
| Revenue (TTM) (Mil) $ | 12.95 |
| EPS (TTM) $ | -0.29 |
| Beta | 2.95 |
| Volatility % | 107.18 |
| 52-Week Range $ | 1.85 - 6.16 |
| Shares Outstanding (Mil) | 102.85 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 4 |
| Positive ROA | N |
| Positive CFROA | N |
| Higher ROA yoy | Y |
| CFROA > ROA | Y |
| Lower Leverage yoy | Y |
| Higher Current Ratio yoy | N |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | N |
| Higher Asset Turnover yoy | Y |